It is reported that, at present, Binhai New Area has gathered more than 1,500 enterprises of innovative drugs, modern traditional Chinese medicine, synthetic biology, medical devices, medical biotechnology, etc. Playing the effect of industrial agglomeration, Binhai New Area is driven by leading enterprises to create an innovation consortium, and through the connection of the chain to make up for the chain, Sphinx, the leading enterprise, has already provided the city's 20-odd pharmaceutical enterprises with the full range of services, from preclinical research to the listing of drugs.
With more and more service enterprises, Sphinx urgently needs to improve the energy efficiency of professional testing, but the purchase of a large number of new equipment, expensive, and sent to professional testing organizations and long cycle. With the help of the industrial mapping of the enterprises in the area, Sphinx found Hanmeng Testing directly, and both parties **** set up a team to realize the cooperation of the whole process of R&D and testing. Sphinx drug R & D (Tianjin) Co., Ltd. chairman Yao Qingjia said: "in the R & D process they help testing, what problems can be timely communication, more efficient, faster R & D. The output value can reach 1.5 billion to 1.5 billion yuan. The output value can reach about 1.5 billion to 2 billion."
Sphinx Drug R&D (Tianjin) Co., Ltd. is an innovative company founded in 2009 by Dr. Yao Qingjia, a doctor who stayed in the U.S., to provide R&D and production outsourcing services for the development of innovative drugs. It specializes in the chemical synthesis of intermediates and APIs for domestic innovative drugs. After ten years of hard work, the company has an experienced and stable R&D and production team, formed Sphinx's characteristic unique technology, accumulated a lot of R&D and production experience, and won the recognition and praise of customers. The company has excellently completed nearly 3,000 R&D projects for drug screening and completed more than 200 projects in clinical phase, some of which have been commercially produced, and has formed a high reputation in the industry.
With 26 invention patents and many unique technologies, the company has been recognized as a national high-tech enterprise since 2012, with more than 10,000 square meters of R & D centers and two production bases, very competitive in the industry; in 2013 and 2016, the company was awarded the "Most Entrepreneurial Potential Enterprise" and "Most Growing Enterprise" respectively by the China Overseas Educated Personnel Venture Park (CEPP), which is one of the 100 enterprises in China. In 2013 and 2016, the company was awarded the title of "Most Entrepreneurial Potential Enterprise" and "Most Growing Entrepreneurial Enterprise" respectively; in 2016, the company was listed on the New Third Board, with the participation of many famous investment organizations; in 2018, the company was selected as a "Gazelle Enterprise" in Tianjin Development Area, and recognized as a "Science and Technology Enterprise" by the Tianjin Municipal Science and Technology Bureau. In 2018, it was selected as "Gazelle Enterprise" in Tianjin Development Area, and recognized as "Science and Technology Enterprise" by Tianjin Science and Technology Bureau; in 2020, the third batch of national science and technology-based small and medium-sized enterprises.
The company has entered a new stage of rapid development through the accumulation of projects in the early stage, and its sales revenue has doubled year after year. The company steadily expanding the production scale at the same time, continue to strengthen the core competitiveness of technology, adhere to the "safety first" and "environmentally friendly" concept, and continue to develop green, continuous automated production and other core technologies.
In order to meet the needs of the rapid development of the company's business, the enterprise has begun to build a 14,000 square meters of R & D headquarters in Tianjin TEDA, preparing for the construction of drug intermediates and APIs of the new production base.
Sphinx, which is y engaged in the field of pharmaceutical outsourcing, has continuously won the trust and affirmation of our commissioned clients with its high standard, high quality and high efficiency services, and has established long-term cooperative relationships with many well-known pharmaceutical companies at home and abroad, which are highly praised by our clients and collaborators.